Influencer marketing in the pharmaceutical industry is a complex issue with reasonable arguments on multiple sides. On the one hand, leveraging individual patients' personal experiences and narratives may help bring an authentic voice to product messaging. This could increase trust and resonance for some audiences skeptical of more traditional promotional content. However, legitimate concerns about transparency and potential conflicts of interest exist if affiliate relationships or sponsored
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
23andMe Scores FDA Clearance for Novel Cancer Immunotherapy Targeting NK Cells
What You Should Know:
- 23andMe Holding Co. (Nasdaq: ME), a genetics and biopharmaceutical company, announced The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for 23ME-01473 (referred to as '1473), paving the way for the first human clinical trial of this promising new therapy.
- With FDA clearance secured, 23andMe plans to initiate a Phase 1 clinical trial in the first half of 2024. This initial study will evaluate the safety and
Read More
PathAI Expands PathExplore Reach to 14 Cancer Types, Fueling Precision Oncology
What You Should Know:
- PathAI, a pioneer in AI-powered pathology, announced a significant expansion of its PathExplore platform, adding six new oncology indications to its arsenal.
- The expansion doubles the platform's reach, now covering 14 different cancer types, and further solidifies PathExplore as the leading tool for characterizing the tumor microenvironment (TME) from H&E-stained whole-slide images (WSIs).
Bridging the Gap in Cancer Research
Despite advances in cancer
Read More
Personalis and ClearNote Join Forces for Early Cancer Detection
What You Should Know:
Personalis, Inc., a leader in advanced genomics for cancer, and ClearNote Health, Inc., a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will expand its pharmaceutical service offerings by distributing ClearNote’s cutting-edge epigenomic 5-hydroxymethylcytosine (5hmC) platform.
Revolutionizing Cancer Detection and Treatment: ClearNote Health's Epigenomics Platform
ClearNote Health's Epigenomics Platform is a
Read More
ObjectiveHealth Secures Growth Investment to Expand Innovative Clinical Research Model
ObjectiveHealth, a pioneer in integrated specialty research, today announced a strategic investment from Vitruvian Partners, a renowned global growth equity firm.
- This strategic investment will fuel ObjectiveHealth's expansion and its mission to revolutionize clinical research by seamlessly integrating trials into the practices of community-based physicians.
Transforming Clinical Trials, One Patient at a Time:
ObjectiveHealth stands out with its innovative approach. They act as a
Read More
Motif Neurotech Raises $18.75M for Implantable Device for Treatment-Resistant Depression
What You Should Know:
- Motif Neurotech, a pioneer in minimally-invasive bioelectronics for mental health, announced today an impressive $18.75 million Series A funding round. Led by Arboretum Ventures, the investment saw participation from prominent players like KdT Ventures, Satori Neuro, and Dolby Family Ventures, alongside existing supporters Divergent Capital and PsyMed Ventures.
- Motif Neurotech's innovative approach represents a potential paradigm shift in mental health treatment.
Read More
Precision Psychiatry: Circular Genomics Secures $8.3M to Tackle Depression with CircRNA Test
What You Should Know:
- Circular Genomics, a pioneer in unlocking the secrets of circular RNA (circRNA) for precision psychiatry and neurology, has secured $8.3 million in a Series A funding round. Led by Mountain Group Partners, this vital investment brings on board new partner UNM Rainforest Innovations and bolsters support from existing investors like Cottonwood Technology Fund and Tramway Venture Partners.
- The new funding will empower Circular Genomics to build and scale commercial
Read More
Invitae Sells Reproductive Health Assets to Natera for Up to $52.5M
What You Should Know:
- Invitae (NYSE: NVTA), a medical genetics company, announced the completion of its sale of certain reproductive health assets, including carrier screening and non-invasive prenatal screening (NIPS), to Natera (NASDAQ: NTRA).
- The transaction is valued at up to $52.5M, comprised of cash, milestone payments, and litigation credits.
Streamlining Focus on Oncology and Rare Disease
This strategic move streamlines Invitae's operations and allows them to focus their
Read More
Leveraging RWD & Tech: Diversifying Clinical Research for Real-World Impact
In today's complex healthcare landscape, real-world data (RWD) is increasingly valued for its information regarding diverse patient populations. Clinical research sites are an essential part of the RWD collection process, which increasingly leverages advanced technologies that enhance data collection, analysis and informed decision-making.
RWD can accelerate development timelines and augment clinical trial insights with key observational results from a wider and more diverse range of
Read More
The New Era of Clinical Trials: Adopting Electronic Informed Consent
The clinical trials landscape continues to evolve and with it, an exponential growth in the adoption of electronic informed consent (eConsent) solutions. These solutions deliver a myriad of benefits for trial sponsors, sites and patients. However, there is still some reluctance to adopt these solutions due to perceived costs associated with implementation and training.
The Importance of eConsent
Clinical trials are evolving with novel designs, hybrid and decentralized
Read More
